A detailed history of Finepoint Capital LP transactions in Arvinas, Inc. stock. As of the latest transaction made, Finepoint Capital LP holds 574,378 shares of ARVN stock, worth $10.6 Million. This represents 1.47% of its overall portfolio holdings.

Number of Shares
574,378
Previous 574,378 -0.0%
Holding current value
$10.6 Million
Previous $15.3 Million 7.48%
% of portfolio
1.47%
Previous 4.4%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$24.46 - $40.4 $862,899 - $1.43 Million
35,278 Added 6.54%
574,378 $15.3 Million
Q1 2024

May 14, 2024

BUY
$36.38 - $52.31 $1.25 Million - $1.8 Million
34,400 Added 6.82%
539,100 $22.3 Million
Q3 2023

Nov 13, 2023

BUY
$19.64 - $28.21 $1.83 Million - $2.63 Million
93,200 Added 22.65%
504,700 $9.91 Million
Q2 2023

Aug 11, 2023

SELL
$21.73 - $31.43 $1.76 Million - $2.54 Million
-80,800 Reduced 16.41%
411,500 $10.2 Million
Q1 2023

May 12, 2023

BUY
$26.15 - $37.26 $1.64 Million - $2.34 Million
62,700 Added 14.59%
492,300 $13.4 Million
Q4 2022

Feb 13, 2023

BUY
$32.47 - $57.24 $993,582 - $1.75 Million
30,600 Added 7.67%
429,600 $14.7 Million
Q3 2022

Nov 10, 2022

BUY
$41.87 - $57.99 $16.7 Million - $23.1 Million
399,000 New
399,000 $17.8 Million

Others Institutions Holding ARVN

About ARVINAS, INC.


  • Ticker ARVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,205,300
  • Market Cap $983M
  • Description
  • Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...
More about ARVN
Track This Portfolio

Track Finepoint Capital LP Portfolio

Follow Finepoint Capital LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Finepoint Capital LP, based on Form 13F filings with the SEC.

News

Stay updated on Finepoint Capital LP with notifications on news.